Copy of Dr. Goetz on Treatment of Metastatic HR+ Breast Cancer

Dr. Goetz on Treatment of Metastatic HR+ Breast CancerПодробнее

Dr. Goetz on Treatment Challenges for ESR1-Mutant Breast CancerПодробнее

Dr. Goetz on Treatment Beyond Progression on CDK4/6 Inhibitors in HR+ Breast CancerПодробнее

Dr. Goetz on the Use of ctDNA in the MONARCH-3 Trial in HR+/HER2- Breast CancerПодробнее

ASCO 2022: Metastatic Breast Cancer Drug Therapy RecapПодробнее

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancerПодробнее

Dr. Goetz on the MONARCH Trials for Breast CancerПодробнее

Dr. Goetz on Survival Data With CDK4/6 Inhibitors in Breast CancerПодробнее

Dr. Goetz Discusses a Secondary Analysis of the MONARCH Trials in Breast CancerПодробнее

Eribulin as Treatment for Metastatic Breast CancerПодробнее

Current Treatment Options for Patients With HER2-Positive Metastatic Breast CancerПодробнее

Surgical Removal of Primary Tumors for Stage IV Metastatic Breast CancerПодробнее

5 symptoms of breast cancer | Warning Signs of breast cancer | Dr Niharika GarachПодробнее

Breast Cancer Genome Guided Therapy (BEAUTY) Study - Matthew Goetz, M.D., & Judy Boughey, M.D.Подробнее

Metastatic breast cancer treatments in developmentПодробнее

CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancerПодробнее

Exploring clinical trials for breast cancer - Mayo ClinicПодробнее

Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment StrategiesПодробнее

Abemaciclib for HR-Positive Metastatic Breast CancerПодробнее